698 
PHARMACOLOGY 
300- 
FiGURE 4. — Disappearance of amphetamine from the 
blood plasma of intact (lower line) and nephrecto- 
mized (upper line) dogs following the intravenous 
injection of amphetamine sulphate (0.66 mg/kg, free 
base). Each point represents the mean plasma am- 
phetamine concentration and each vertical bar is 1 
S.D. The mean values of the pharmacokinetic param- 
eters were calculated: intact dogs (n = 11), B = 
263 ng m\-\ Wz = 4.50 hours, V'd* = 3.58 litres 
kg~S Coverall = 9.18 ml min~^ kg~^; nephrecto- 
mized dogs (n = 8), B =:: 258 ng ml-^ tVz — 5.69 
hours, V'd* =: 3.38 litres kg-^ C'„rveMi = 6.88 ml 
min"^ kg~\ 
other species. In: International symposium on am- 
phetamines and related compounds. Edited by E. 
Costa and S. Garattini. New York: Raven Press, 
pp. 121-138, 1970. 
12. Lefpler, E. B., Spencer, H, M., and Burger, A. 
Dissociation constants of adrenergic amines. J. 
Am. Chem. Soc. 73:2611-2613, 1951. 
13. Lewis, G. P. The importance of ionization in the 
activity of sympathomimetic amines. Br. J. Phar- 
mac. 9:488-493, 1954. 
14. Vree, T. B., Muskens, A. T., and Van Rossum, 
J. M. Some physico-chemical properties of amphet- 
amine and related drugs. J. Pharm. Pharmac. 
21:774-775, 1969. 
15. NooNAN, J. S., MuRDiCK, P. W., and Ray, R. S. A 
method for detecting amphetamine using gas chro- 
matography of a halogenated derivative. J. Phar- 
mac. Exp. Ther. 168:205-209, 1969. 
16. BORGA, 0., AZARNOFF, D. L., Plym Forshell, G., 
and Sjogvist, F. Plasma protein binding of tri- 
cyclic antidepressants in man. Biochem. Pharmac. 
18:2135-21:3, 1969. 
17. Franksson, G., and Anggard, E. The plasma pro- 
tein binding of amphetamine, catecholamines and 
related compounds. Acta Pharmac Tox. (Kbh.) 
28:209-214, 1970. 
18. Neff, C. a., Davis, L. E., and Baggot, J. D. A 
comparative study of the pharmacokinetics of quin- 
idine. Am. J. Vet. Res. (In press) 1971. 
19. DOMINQUEZ, R. Kinetics of elimination, absorp- 
tion and volume of distribution in the organism. 
Med. Physics II 476-489, 1950. 
20. Fuller, R. W., and Hines, C. W. Tissue levels of 
chloroamphetamines in rats and mice. J. Pharm. 
Sci. 56:302-303, 1967. 
21. Brzezinski, J. Rate of amphetamine absorption 
and excretion in rats. Acta Pol. Pharm. 25:91-96, 
1968. 
22. SiEGEL, M., Ellison, T., Silverman, A. G., and 
Okun, R. Tissue distribution of dZ-^H-amphetamine 
HCl in tolerant and nontolerant cats. Proc. West. 
Pharmac. Soc. 11:90-94, 1968. 
23. Corker, E. The secretion of certain drugs into the 
bovine rumen-reticulum. M.S. Thesis, University of 
Minnesota, Minneapolis, 1966. 
24. Jenkins, W. L. Drug distribution across ruminal 
epithelium. Ph.D. Thesis, University of Missouri, 
Columbia, 1969. 
25. Caldwell, J., Dring, L. G., and Williams, R. T. 
The biliary excretion of amphetamine and meth- 
amphetamine in the rat. Biochem. J. 124:16P, 
1971. 
26. Beckett, A. H., and Rowland, M. Urinary ex- 
cretion kinetics of amphetamine in man. J. Pharm. 
Pharmac. 17:628-639, 1965. 
27. Rowland, M. Amphetamine blood and urine lev- 
els in man. J. Pharm. Sci. 58:508-509, 1969. 
28. Asatoor, a. M., Galman, B. R., Johnson, J. R., 
and Milne, M.D. The excretion of dexamphet- 
amine and its derivatives. Br. J. Pharmac. 24:293- 
300, 1965. 
29. Beckett, A. H., Rowland, M., and Turner, P. 
Influence of urinary pH on excretion of amphet- 
amine. Lancet. i:303, 1965. 
30. Beckett, A. H., Salmon, J. A., and Mitchard, 
M. The relation between blood levels and urinary 
excretion of amphetamine under controlled acidic 
and under fluctuating urinary pH values using 
"C-amphetamine. J. Pharm. Pharmac. 21:251-258, 
1-969. 
31. Groppetti, a., and Costa, E. Factors affecting 
the rate of disappearance of amphetamine in rats. 
Int. J. Neuropharmac. 8:209-215, 1969. 
32. Reidenberg, M. M., Odar-Cederlof, I., von Bahr, 
C, Borga, 0., and Sjoqvist, F. Protein binding of 
diphenylhydantoin and desmethylimipramine in 
plasma from patients with poor renal function. N. 
England J. Med. 285:264-267, 1971. 
DISCUSSION 
Chairman Cohen: Dr. Baggot's interesting 
paper is now open for discussion. 
Jules Cass, Veteran's Administration, 
Washington, D.C. : These are one dose experi- 
ences, are they? One wonders, of course, in the 
repeated dose, what sorts of shifts occur in the 
